Headache News and Research RSS Feed - Headache News and Research

Duke-NUS study highlights Zika virus structure and behaviour

Duke-NUS study highlights Zika virus structure and behaviour

An important breakthrough in understanding the Zika virus structure and its behaviour has been highlighted in a study by Duke-NUS Medical School scientists. [More]
AAN’s updated guideline on botulinum toxin use covers four neurologic disorders

AAN’s updated guideline on botulinum toxin use covers four neurologic disorders

The American Academy of Neurology has updated its 2008 guidelines on the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm and migraine headache, based on recent research. [More]
AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie, a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis. [More]
VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

VIEKIRAX and EXVIERA achieve high SVR rates in GT1 and GT4 hepatitis C virus infected patients

AbbVie, a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12). [More]
New KidsMD Alexa skill device allows parents to get easier to access medical information

New KidsMD Alexa skill device allows parents to get easier to access medical information

"My child has a fever of 101. Should I be concerned?" Through a new skill created for Amazon Alexa-enabled devices, parents will now be able to ask Alexa a variety of questions around fever and other common symptoms. The KidsMD Alexa skill was developed by the Innovation & Digital Health Accelerator team at Boston Children's Hospital and launched today. [More]
Inflectra (infliximab-dyyb) approved for multiple indications

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. [More]
Janssen announces CHMP positive opinion for use of paliperidone palmitate 3-monthly injection for schizophrenia treatment

Janssen announces CHMP positive opinion for use of paliperidone palmitate 3-monthly injection for schizophrenia treatment

Janssen UK announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the use of paliperidone palmitate 3-monthly injection for the maintenance treatment of schizophrenia in the European Union. [More]
NICE issues positive guidance on use of electroCore’s gammaCore treatment for migraine and cluster headache

NICE issues positive guidance on use of electroCore’s gammaCore treatment for migraine and cluster headache

The UK’s National Institute of Health and Care Excellence has published guidance that electroCore’s non-invasive vagus nerve stimulation treatment (gammaCore) for the prevention and acute treatment of migraine and cluster headache is safe and can now be used in the NHS. [More]
Investigators predict that new pneumonia epidemic in Beijing will likely to continue for longer time

Investigators predict that new pneumonia epidemic in Beijing will likely to continue for longer time

Mycoplasma pneumoniae infections began rising in Beijing last spring, and by December, this pathogen was found in more than half of hospitalized children suffering from pneumonia in that city, according to investigators from the Capital Institute of Pediatrics, Beijing, China. [More]
Sleep problems predict chronic pain in emerging adults

Sleep problems predict chronic pain in emerging adults

For at least some groups of "emerging adults," sleep problems are a predictor of chronic pain and worsening pain severity over time, suggests a study in PAIN, the official publication of the International Association for the Study of Pain. [More]
Symptom Tracking App for Concussions helps athletes, parents deal with head injuries

Symptom Tracking App for Concussions helps athletes, parents deal with head injuries

Thirteen-year-old Madeline Yunker fell hard during a soccer match three years ago, striking her head on the turf with enough force to cause a concussion. [More]
Four commonly used medications to treat pregnant women with migraines may not be safe

Four commonly used medications to treat pregnant women with migraines may not be safe

According to doctors at Wake Forest Baptist Medical Center, medications and treatments long considered safe to treat pregnant women with migraines may not be. [More]
IUPUI assistant professor to study role of deficient pain modulatory systems on post-traumatic headaches

IUPUI assistant professor to study role of deficient pain modulatory systems on post-traumatic headaches

An assistant professor in the Department of Kinesiology in the IU School of Physical Education and Tourism Management at Indiana University-Purdue University Indianapolis has been awarded a grant to study the role of deficient pain modulatory systems on chronic post-traumatic headaches afflicting hundreds of thousands of people with mild traumatic brain injuries. [More]
Concussion-related symptoms improve following initial session of OMT

Concussion-related symptoms improve following initial session of OMT

Two case reports published in The Journal of the American Osteopathic Association document improvements in concussion-related symptoms following an initial session of osteopathic manipulative treatment (OMT). [More]
UCI researchers get $8 million to help develop new vaccine for Q fever

UCI researchers get $8 million to help develop new vaccine for Q fever

A University of California, Irvine scientific team led by infectious diseases researchers Philip Felgner and Aaron Esser-Kahn has received $8 million from the U.S. Department of Defense's Defense Threat Reduction Agency to help develop a new vaccine for Q fever. [More]
Yellow fever outbreak in Angola kills 178 people

Yellow fever outbreak in Angola kills 178 people

Angola is grappling with a yellow fever outbreak, which has infected more than 450 people and killed 178 – the first epidemic of the disease to hit the country in 30 years. [More]
Kids with minor head injuries may not require hospitalization, study suggests

Kids with minor head injuries may not require hospitalization, study suggests

Challenging the longstanding practice of keeping all children with head injuries in the hospital overnight, new research from Ann & Robert H. Lurie Children's Hospital suggests that patients with simple skull fractures can be sent home safely if they have no evidence of brain injury and no neurological symptoms. [More]
Sandia engineers aim to develop autonomous device to passively monitor mosquito-borne diseases

Sandia engineers aim to develop autonomous device to passively monitor mosquito-borne diseases

Mosquitoes are deadly efficient at spreading disease. Despite vaccines and efforts to eradicate the pesky insects, they continue to infect humans with feared diseases like Zika virus, malaria and West Nile virus. [More]
Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
Advertisement
Advertisement